Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Clinical Efficacy and Mechanism Research of Getong Tongluo Capsule in Ischemic Stroke

7. juli 2026 opdateret af: Nanfang Hospital, Southern Medical University
The purpose of this single-center, randomized, double-blind, controlled trial is to clarify the clinical efficacy and safety of Getong Tongluo Capsule in patients with ischemic stroke. Combined with gut microbiome and metabolomics techniques, investigators will explore whether this medicine exerts neuroprotective effects via the gut-brain axis. Investigators will further verify its pharmacological mechanism through animal experiments to provide evidence for its clinical application.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

216

Fase

  • Ikke anvendelig

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  1. Voluntarily sign the informed consent form
  2. Aged between 18 and 80 years old
  3. Conform to the diagnosis of acute ischemic stroke referring to the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke (2023)
  4. Hospital admission within 21 days after disease onset

Exclusion Criteria:

  1. Patients with mild or no neurological deficits on admission: those with a score of 0 on the Modified Rankin Scale (mRS) at admission (defined as completely asymptomatic).
  2. Patients with severe baseline disability: those with a pre-stroke mRS score ≥ 3 (indicating moderate to severe disability requiring partial or full assistance with activities of daily living).
  3. Patients with transient ischemic attack, concomitant cerebral hemorrhage or subarachnoid hemorrhage; those complicated with brain tumor, Alzheimer's disease, psychiatric disorders, or suspected pre-stroke cognitive dysfunction.
  4. Patients complicated with severe cardiac diseases including valvular heart disease, infective endocarditis, myocardial infarction and heart failure; severe hepatic or renal insufficiency, respiratory failure, malignant tumors, or massive gastrointestinal hemorrhage.
  5. Patients who received any preparations containing the same active ingredients as the study drug (e.g., Pueraria lobata) within 2 weeks prior to stroke onset.
  6. Patients with a history of allergy to the study drug or preparations with identical active ingredients.
  7. Patients who received antibiotics within 1 month before onset; those taking probiotics or prebiotics long-term; patients with a past or in-hospital confirmed gastrointestinal disease history.
  8. Pregnant and lactating women.
  9. Patients deemed unsuitable for participation in this trial at the investigator's discretion.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Behandlingsgruppe
Medicin: Getong Tongluo Capsule
Oral proprietary Chinese medicine for convalescent ischemic stroke. Subjects take 2 capsules (0.25 g each), twice daily, on top of guideline-standardized antiplatelet, lipid-lowering, antihypertensive and hypoglycemic routine stroke treatment. Treatment period ranges from 14±7 days to 6 months after stroke onset.
Medicin: Standard Routine Therapy for Ischemic Stroke
Individualized guideline-directed basic stroke care including antiplatelet, lipid-regulating, blood pressure and glucose lowering medications, provided to all participants in both treatment and placebo arms throughout the study.
Placebo komparator: Placebo gruppe
Medicin: Standard Routine Therapy for Ischemic Stroke
Individualized guideline-directed basic stroke care including antiplatelet, lipid-regulating, blood pressure and glucose lowering medications, provided to all participants in both treatment and placebo arms throughout the study.
Andet: Matched Starch Placebo Capsule
Starch-filled blank capsules identical to Getong Tongluo Capsule in appearance, size and taste. Subjects take 2 capsules (0.25 g each), twice daily together with standardized basic stroke therapy, for 14±7 days to 6 months post stroke.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Distribution of modified Rankin Scale (mRS) scores
Tidsramme: Baseline, 3-month follow-up and 6-month follow-up
Scores range from 0 (no symptoms) to 6 (death); higher scores indicate poorer functional recovery
Baseline, 3-month follow-up and 6-month follow-up
Incidence of adverse events
Tidsramme: Through study completion, an average of 6 months
Through study completion, an average of 6 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Athens Insomnia Scale (AIS) score
Tidsramme: Baseline, 3-month follow-up and 6-month follow-up
Total score ranges from 0 to 24; higher scores indicate more severe insomnia (worse sleep condition)
Baseline, 3-month follow-up and 6-month follow-up
Proportion of Traditional Chinese Medicine(TCM) Syndrome Improvement
Tidsramme: Baseline, 3-month follow-up and 6-month follow-up
The scale evaluates six TCM syndrome elements (endogenous wind, internal fire, blood stasis, phlegm-dampness, qi deficiency, yin deficiency) with weighted symptom scores for each element. Higher subscores for each syndrome element represent more severe relevant syndrome manifestations.
Baseline, 3-month follow-up and 6-month follow-up
Activities of Daily Living (ADL) score
Tidsramme: Baseline, 3-month follow-up and 6-month follow-up
Total score ranges from 0 to 100; higher scores indicate superior independent daily function
Baseline, 3-month follow-up and 6-month follow-up
Hamilton Depression Rating Scale (HAMD) score
Tidsramme: Baseline, 3-month follow-up and 6-month follow-up
Total score ranges from 0 to 52; higher scores indicate more severe depressive symptoms
Baseline, 3-month follow-up and 6-month follow-up
Hamilton Anxiety Rating Scale (HAMA) score
Tidsramme: Baseline, 3-month follow-up and 6-month follow-up
Total score ranges from 0 to 56; higher scores indicate more severe anxiety symptoms
Baseline, 3-month follow-up and 6-month follow-up
Montreal Cognitive Assessment (MoCA) score
Tidsramme: Baseline, 3-month follow-up and 6-month follow-up
Total score ranges from 0 to 30; higher scores indicate better cognitive function.
Baseline, 3-month follow-up and 6-month follow-up
MMSE score
Tidsramme: Baseline, 3-month follow-up and 6-month follow-up
Total score ranges from 0 to 30; higher scores indicate better cognitive performance
Baseline, 3-month follow-up and 6-month follow-up
Incidence rate of drug-related adverse reactions
Tidsramme: Through study completion, an average of 6 months
Through study completion, an average of 6 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Nanfang Hospital, Southern Medical University

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. august 2026

Primær færdiggørelse (Anslået)

31. juli 2029

Studieafslutning (Anslået)

31. januar 2030

Datoer for studieregistrering

Først indsendt

29. juni 2026

Først indsendt, der opfyldte QC-kriterier

7. juli 2026

Først opslået (Faktiske)

8. juli 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

8. juli 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

7. juli 2026

Sidst verificeret

1. juli 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • NFEC-2026-409

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Getong Tongluo Capsule

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Romania

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner